As of September 30, 2025, Taysha had $297.3 million in cash and cash equivalents. The Company expects that its current cash resources will support planned operating expenses and capital requirements into 2028.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Is TSHA a Buy, Before Earnings?
- Taysha Gene Therapies’ REVEAL Adult Study: A New Hope for Rett Syndrome?
- Taysha Gene Therapies initiated with a Strong Buy at Raymond James
- Strategic Advantage and Positive Outlook: Taysha Gene Therapies Maintains Buy Rating
- Taysha Regains Full Rights to TSHA-102 Program